T-cell activation via presentation of tumor-associated antigen or neoantigen by major histocompatibility complex molecule on dendritic cell

This entry describes a **cellular immunological process** rather than a single molecular target. The process involves **dendritic cells**, which are professional antigen-presenting cells, capturing and processing multiple **tumor-associated antigens** (TAAs) or **neoantigens** from cancerous tissue. These processed peptides are loaded onto **major histocompatibility complex (MHC) molecules**—primarily class I for CD8+ cytotoxic T lymphocytes and class II for CD4+ helper T lymphocytes—and presented at the surface of the dendritic cell.\n\nUpon migration to secondary lymphoid organs, these mature dendritic cells interact with naïve or memory **T-cells**, providing three essential signals for full activation:\n1. Recognition via the peptide-MHC-TCR interaction,\n2. Co-stimulatory molecule engagement,\n3. Cytokine signaling that shapes the immune response profile.\n\nThis mechanism is central to anti-tumor immunity because it enables highly specific targeting and destruction of cancerous cells expressing these unique peptides, especially those derived from somatic mutations (**neoantigens**) that are not present in normal tissues. This specificity underpins several immunotherapeutic strategies such as personalized cancer vaccines and adoptive transfer therapies using engineered or expanded autologous T-cells.\n\nHowever, this is not a single protein target but rather an essential stepwise event within the broader immune response pathway; thus, it does not fit standard molecular target conventions like \"receptor\" or \"enzyme.\" It is best described as an *immune functional axis* involving multiple components—dendritic cell, MHC molecule, peptide antigen/neoantigen—which together enable therapeutic manipulation through vaccination strategies aimed at enhancing anti-tumor immunity while minimizing off-target effects.\n\nBecause this entry refers to a multi-component cellular process rather than a discrete molecular entity, it should be flagged as \"is_incorrect\" if strict adherence to single-molecule/receptor definitions is required.

Other names

Antigen presentation by dendritic cellTumor antigen presentation to T cellsNeoantigen presentation by MHC on dendritic cellDendritic cell-mediated T-cell activation

Induction of tumor-specific or neoantigen-specific cytotoxic T lymphocyte responses via MHC-peptide complex recognition by the T-cell receptor, leading to targeted killing of tumor cells